早期痴呆症的炎症性变化与莱维体
Talene A Yacoubian1, Hongwei Qin2, Amy Amara1
1Department of Neurology, Birmingham, AL, United States.
Frontiers in neurology
|September 11, 2025
概括
患有勒维体的早期痴呆症 (DLB) 显示成熟中性粒细胞减少,表明免疫细胞发生变化. 这项小型研究表明,在轻度认知障碍-莱维体 (MCI-LB) 患者中,潜在的炎症标志物.
科学领域:
- 神经免疫学 神经免疫学
- 神经退行性疾病的神经退行性疾病
- 综核蛋白病变 (Synucleinopathies) 是一种同核蛋白病变.
背景情况:
- 在帕金森病 (PD) 中记录了炎症变化,但对患有勒维体痴呆症 (DLB) 的了解较少.
- 以前的研究表明DLB的炎症反应,但早期免疫细胞的变化仍然不清楚.
研究的目的:
- 为了研究早期痴呆症的免疫细胞变化与勒维体 (DLB).
- 探索轻度认知障碍-利维体 (MCI-LB) 中潜在的炎症标志物,作为DLB的早期指标.
主要方法:
- 一个由9名轻度认知障碍-莱维体 (MCI-LB) 患者组成的探索性队列与新发帕金森病 (PD) 和健康对照进行了比较.
- 临床评估包括运动障碍学会-联合帕金森病评级表 (MDS-UPDRS) 和认知测试.
- 血液样本使用流动细胞计和细胞因子/化学因子试验进行分析.
主要成果:
- 与PD参与者相比,MCI-LB受试者表现出明显较差的认知综合分数.
- 与健康对照人群相比,在MCI-LB患者中观察到成熟中性粒细胞的显著减少60%.
- 在组之间发现了嗅觉识别,日常生活活动和MDS-UPDRS分数的差异.
结论:
- 这项探索性研究揭示了与健康对照人群相比,MCI-LB中先天性免疫细胞的变化.
- 这些发现表明,在DLB的早期阶段,可能存在免疫细胞的改变.
- 需要进行更大的队列研究来验证这些初步发现.
相关概念视频
Dementia
526
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
526
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Neural Regulation
43.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.2K
Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
Alzheimer's Disease: Treatment
827
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
827
Inflammation
61.7K
Overview
61.7K


